Best supportive care versus palliative chemotherapy in nonsmall-cell lung cancer

Current Opinion in Oncology

Volumn 14, Issue 4, 2002, Pages 384-388

  Medley, Louise ^a   Cullen, Michael ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; MITOMYCIN; NAVELBINE; PACLITAXEL; VINBLASTINE;

ADVANCED CANCER; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; GRANULOCYTOPENIA; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; AGE; AGED; LUNG TUMOR; PALLIATIVE THERAPY; PATHOLOGY; PATIENT CARE PLANNING; QUALITY OF LIFE;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMAN; LUNG NEOPLASMS; PALLIATIVE CARE; PATIENT CARE PLANNING; QUALITY OF LIFE; HUMANS;

EID: 0035988120     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200207000-00002     Document Type: Review

References (28)

1. Current standards of care in small-cell lung cancer and non-small cell lung cancer
2. Survival analysis of untreated patients with non-small-cell lung cancer
3. Best supportive care in non-small cell lung cancer: Is there a role for radiotherapy and chemotherapy?
4. Best supportive care has had its day
5. Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life
6. Gemcitabine plus best supportive care (BSC) vs. BSC in inoperable non-small cell lung cancer: A randomised trial with quality of life as the primary outcome
7. A multicenter, randomised, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy naïve patients with metastatic or non-resectable localised non-small cell lung cancer
8. Prospective randomised trial of docetaxel vs. BSC in patients with NSCLC previously treated with platinum based chemotherapy
9. Palliative chemotherapy: No longer a contradiction in terms
10. A systematic overview of chemotherapy effects in NSCLC
11. European perspectives on paclitaxel/platinum-based therapy for advanced NSCLC
12. Randomised trial of paclitaxel plus supportive care vs. supportive care for patients with advanced NSCLC
13. Weekly paclitaxel in advanced non-small cell lung cancer
14. Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimes followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer
15. Phase III randomised trial of docetaxel in combination with cisplatin or carboplafin or vinorelbine plus cisplatin in advanced non-small cell lung cancer: Interim analysis
16. The current status of docetaxel for advanced non-small cell lung cancer
17. Gemcitabine and carboplatin for patients with advanced NSCLC
18. A randomised phase III trial of four chemotherapy regimes in advanced non-small cell lung cancer (NSCLC)
19. Randomised trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
20. A randomised phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small-cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
21. The benefits of chemotherapy in patient subgroups with unresectable non-small cell lung cancer
22. The ELVIS trial: A phase III study of single agent vinorelbine as first line treatment in elderly patients with advanced non-small cell lung cancer
23. Management of elderly patients with lung cancer
24. Review of two phase III randomised trials of single agent docetaxel in previously treated advanced NSCLC
25. Randomised phase III trial of docetaxel vs. vinorelbine or ifosfamide in patients with advanced NSCLC previously treated with a platinum-containing agent
26. Novel approaches for the treatment of non-small cell lung cancer
27. European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer
28. Treatment of advanced NSCLC: A review of current randomised clinical trials and an examination of emerging therapies